214 related articles for article (PubMed ID: 32124127)
1. ASO Author Reflections: Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma-Predictors of Disease Progression and Performance Status Decline.
Paniccia A; Zureikat A
Ann Surg Oncol; 2020 Aug; 27(8):2972-2973. PubMed ID: 32124127
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: Prognostic Index after Neoadjuvant Chemotherapy (PINC) in Pancreatic Ductal Adenocarcinoma as Novel Tumor Regression Grading System.
Redegalli M; Schiavo Lena M
Ann Surg Oncol; 2022 Jun; 29(6):3503. PubMed ID: 35187623
[No Abstract] [Full Text] [Related]
3. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.
Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J
J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644
[TBL] [Abstract][Full Text] [Related]
4. ASO Author Reflections: The Role of Neoadjuvant Chemotherapy in Invasive Intraductal Mucinous Neoplasms of the Pancreas.
Fogliati A; Truty MJ
Ann Surg Oncol; 2024 May; 31(5):2967-2968. PubMed ID: 38485866
[No Abstract] [Full Text] [Related]
5. Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?
Salvia R; Malleo G; Maggino L; Milella M; Bassi C
Updates Surg; 2020 Jun; 72(2):321-324. PubMed ID: 32445032
[No Abstract] [Full Text] [Related]
6. ASO Author Reflections: Systemic Immune-Inflammation Index (SII) as a Biomarker of Response to Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma.
Murthy P; Boone BA
Ann Surg Oncol; 2020 Mar; 27(3):907-908. PubMed ID: 31823171
[No Abstract] [Full Text] [Related]
7. ASO Author Reflections: Neoadjuvant Chemoradiotherapy for Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy Changes Body Composition Influencing Long-term Outcomes.
Takaichi S; Tomimaru Y; Kobayashi S; Toya K; Sasaki K; Iwagami Y; Yamada D; Noda T; Takahashi H; Asaoka T; Tanemura M; Doki Y; Eguchi H
Ann Surg Oncol; 2023 Apr; 30(4):2469-2470. PubMed ID: 36567385
[No Abstract] [Full Text] [Related]
8. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
9. History of preoperative therapy for pancreatic cancer and the MD Anderson experience.
Gaskill CE; Maxwell J; Ikoma N; Kim MP; Tzeng CW; Lee JE; Katz MHG
J Surg Oncol; 2021 May; 123(6):1414-1422. PubMed ID: 33831256
[TBL] [Abstract][Full Text] [Related]
10. [I. The Efficacy of Preoperative Adjuvant Treatment for Pancreatic Ductal Adenocarcinoma Based on the Resectability Criteria according to JPS 7th].
Shinkai T; Kato H; Hayasaki A; Murata Y; Kishiwada M; Isaji S
Gan To Kagaku Ryoho; 2017 Oct; 44(10):837-844. PubMed ID: 29066676
[No Abstract] [Full Text] [Related]
11. A commentary on 'Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study'.
Zhong F; Xieb C; Peng X; Luo J; Yang H
Int J Surg; 2024 Mar; 110(3):1331-1332. PubMed ID: 38051933
[No Abstract] [Full Text] [Related]
12. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
13. Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability.
Mondo EL; Noel MS; Katz AW; Schoeniger LO; Hezel AF
J Clin Oncol; 2013 Jan; 31(3):e37-9. PubMed ID: 23233707
[No Abstract] [Full Text] [Related]
14. ASO Author Reflections: Do Distinct Patterns of Recurrence Impact the Prognosis of Patients With Resected Pancreatic Ductal Adenocarcinoma?
Groot VP; Wolfgang CL; He J
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):806-807. PubMed ID: 30298312
[No Abstract] [Full Text] [Related]
15. ASO Author Reflections: Surgical Predictors for Survival in Patients Undergoing Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
Korrel M; Abu Hilal M; Besselink MG
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):854-855. PubMed ID: 32699928
[No Abstract] [Full Text] [Related]
16. [Optimal duration and timing of adjuvant chemotherapy after resection for pancreatic ductal adenocarcinoma].
Strobel O; Büchler MW
Chirurg; 2014 Jun; 85(6):543. PubMed ID: 24824005
[No Abstract] [Full Text] [Related]
17. ASO Author Reflections: Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma.
Tamburrino D; Guarneri G; Capurso G; Falconi M
Ann Surg Oncol; 2021 Apr; 28(4):2323-2324. PubMed ID: 32929602
[No Abstract] [Full Text] [Related]
18. Is Surgery-first Still a Reasonable Option in the Era of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer?
Saharia A; Potter LM; Baio F; Elaileh A; Mobley C; Ghobrial RM; Abdelrahim M; Heyne K
Am J Clin Oncol; 2020 Apr; 43(4):298-304. PubMed ID: 31895096
[TBL] [Abstract][Full Text] [Related]
19. ASO Author Reflections: Preceding Systemic Chemotherapy Might Provide Better Prognosis for Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology.
Ariake K; Mizuma M; Motoi F; Unno M
Ann Surg Oncol; 2021 Oct; 28(11):6255-6256. PubMed ID: 33634387
[No Abstract] [Full Text] [Related]
20. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
